ClinicalTrials.gov
ClinicalTrials.gov Menu

Mobile Enhancement of Motivation in Schizophrenia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03059771
Recruitment Status : Completed
First Posted : February 23, 2017
Last Update Posted : July 30, 2018
Sponsor:
Collaborators:
Indiana Clinical and Translational Sciences Institute
American Psychological Foundation
Indiana University-Purdue University Indianapolis Department of Psychology
Information provided by (Responsible Party):
Michelle Salyers, Indiana University

Brief Summary:
Motivation deficits are a strong determinant of poor functional outcomes in people with schizophrenia. Mobile interventions are a promising approach to improving these deficits, as they can provide frequent cues and reinforcements that support goal-directed behavior. The primary aims of this study are to conduct a pilot study using a randomized design to 1) Test the feasibility and acceptability of a personalized mobile text message intervention, Mobile Enhancement of Motivation in Schizophrenia (MEMS) and to 2) Test the preliminary effectiveness of MEMS compared to a control condition.

Condition or disease Intervention/treatment Phase
Schizophrenia Schizo Affective Disorder Psychosis Behavioral: Mobile Enhancement of Motivation (MEMS) Behavioral: Control Not Applicable

Detailed Description:
Objectives: Motivation deficits are one of the strongest determinants of poor functional outcomes in people with schizophrenia. Mobile interventions are a promising approach to improving these deficits, as they can provide frequent cues and reinforcements that support goal-directed behavior. The objective of this study is to conduct a pilot study using a randomized design to 1) Test the feasibility and acceptability of a personalized mobile text message intervention, Mobile Enhancement of Motivation in Schizophrenia (MEMS) and to 2) Test the preliminary effectiveness of MEMS compared to a control condition. Methods: Up to forty outpatients with a schizophrenia-spectrum disorder will be recruited. All participants will set individualized recovery goals to complete over an eight-week period; those randomized to receive MEMS will also receive three sets of personalized, interactive text messages each weekday to reinforce and cue goal completion. Before and after the eight-week period, participants in both groups will complete validated measures of motivation. Both groups will also report their goal attainment after eight weeks. Results: It is anticipated that those in the MEMS group will demonstrate greater goal attainment and improvements in motivation compared to the control group. Discussion: This project will test the initial feasibility, acceptability, and effectiveness of a novel intervention for improving one of the most debilitating aspects of schizophrenia.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 59 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Mobile Enhancement of Motivation in Schizophrenia: A Pilot Trial of a Personalized Text Message Intervention for Motivation Deficits
Actual Study Start Date : February 28, 2017
Actual Primary Completion Date : January 16, 2018
Actual Study Completion Date : January 16, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Schizophrenia

Arm Intervention/treatment
Experimental: Mobile Enhancement of Motivation (MEMS)
Facilitators will first collaboratively help participants set personal recovery-goals using Collaborative Goal Technology (Clarke et al., 2006). Participants will then receive three sets of interactive text messages each weekday for eight weeks to reinforce and cue goal completion.
Behavioral: Mobile Enhancement of Motivation (MEMS)
The MEMS group will engage in a goal-setting session and then receive personalized text-messages to support goal attainment.

Active Comparator: Control
Participants will only engage in a goal-setting session where facilitators will collaboratively help participants set personal recovery-goals using Collaborative Goal Technology (Clarke et al., 2006).
Behavioral: Control
The control group will only engage in a goal-setting session.




Primary Outcome Measures :
  1. Goal completion [ Time Frame: follow-up (8 weeks) ]
    The percentage of baseline goals participants completed over the eight-week period will be assessed at the follow-up assessment.


Secondary Outcome Measures :
  1. Motivation and Pleasure Scale-Self-Report (MAP-SR) [ Time Frame: baseline and follow-up (8 weeks) ]
    The MAP-SR is a self-report measure 15-item self-report measure that assesses participant's level of motivation and pleasure in several domains, including work and recreational activities. It has been found to be valid and reliable in a schizophrenia-spectrum sample (Llerena, et al., 2013).

  2. Intrinsic Motivation Index [ Time Frame: baseline and follow-up (8 weeks) ]
    The 3-item Intrinsic Motivation Index (Nakagami et al., 2008) from the clinician-rated Quality of Life Scale (Heinrichs et al., 1984) will be used to assess trait-like intrinsic motivation.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Schizophrenia-spectrum diagnosis
  • Have a text-message enabled cell-phone
  • Are a current client at a participating community mental health center
  • Are in a non-acute phase of illness or have no medication changes or hospitalizations in the prior 30 days
  • Demonstrate a minimum of moderate motivation impairments according to the Clinical Assessment Interview for Negative Symptoms (CAINS; Kring et al., 2013)
  • Have an English reading level at or above the fourth grade according to the Graded Word List (Pray & Ross, 1969)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03059771


Locations
United States, Indiana
Midtown Community Mental Health Center
Indianapolis, Indiana, United States, 46208
Sponsors and Collaborators
Indiana University
Indiana Clinical and Translational Sciences Institute
American Psychological Foundation
Indiana University-Purdue University Indianapolis Department of Psychology

Responsible Party: Michelle Salyers, Professor and Director of Clinical Psychology, Indiana University
ClinicalTrials.gov Identifier: NCT03059771     History of Changes
Other Study ID Numbers: 1701070796
First Posted: February 23, 2017    Key Record Dates
Last Update Posted: July 30, 2018
Last Verified: July 2018

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Schizophrenia
Mood Disorders
Psychotic Disorders
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders